Fact CheckerSign in

NCT06603285Not yet recruiting

A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin

A Multi-center, Prospective Study to Observe the Safety, Tolerability, and Efficacy of Remodulin® in Patients With Pulmonary Arterial Hypertension

Source: ClinicalTrials.gov · Last updated 15 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
20 (estimated)
First submitted
22 Aug 2024
Start date
16 Oct 2025
Primary completion date
31 May 2029
Lead sponsor
Excelsior
NCT number
NCT06603285

What you commit to

  • Study type: Observational
  • Planned participants: 20
  • From 16 Oct 2025 to the primary completion date, 31 May 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Active treatment with injectable prostanoids different from subcutaneous/intravenous treprostinil

Who the study is looking for

  • Diagnosed with symptomatic idiopathic or heritable PAH classified as WHO functional class III and IV symptoms.
  • PAH patient, who met NHI criteria, will be scheduled to receive subcutaneous/intravenous treprostinil treatment.
  • Ability to adhere to the study visit schedule and understand and comply with all protocol requirements.
  • Will provide completed and signed written informed consents

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.